Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.

At week 52, increases in triacylglycerol from baseline were seen with both canagliflozin doses, whereas a decrease was observed with sitagliptin; the difference between canagliflozin and sitagliptin did not reach statistical significance (Table 2 ).

also in 111,027 other papers